Summarizing the State of Hyperfunction Theories of Aging

A recent study identified the thymus hormone thymulin as a molecule with the potential to reduce inflammation in an age-dependent manner. Treating cancer-bearing mice with this molecule made other cancer treatments more effective [1].

Iron metabolism is strongly connected to oxidative stress, the excessive production of reactive oxygen species and other oxidative molecules that outpaces the ability of cells to avoid, resist, or repair the consequent damage.

That we cannot accurately and robustly measure biological age is a major impediment to the development of rejuvenation therapies.

Use of hormone therapy later in life was associated with lower risk of developing dementia, according to a study published August 12, 2026, in Neurology, the medical journal of the American Academy of Neurology.

Age-related cognitive decline is a major social and medical challenge, but its mechanisms remain poorly understood; prevention and therapy are unsatisfactory.

Attentionally directed oculomotor training may engage circuits implicated in gamma-band modulation and early Alzheimer’s disease (AD) pathophysiology, yet its effects across mild cognitive impairment (MCI) risk strata remain unclear.

Verbal memory decline is an early marker of dementia. This study aims to identify significant lifestyle correlates of verbal learning and memory among older adults to inform intervention targets for maintaining cognitive health in late life.

Growth hormone (GH) exerts complex effects on metabolism, cognition, and overall physiological well-being, and its secretion is highly regulated by the circadian clock.

The blood-cerebrospinal fluid barrier (BCB) maintains central nervous system homeostasis. Its dysfunction, reflected by an increased cerebrospinal fluid/plasma albumin ratio (Q-Alb), has been reported in several neurodegenerative diseases. However, the diagnostic utility of Q-Alb in dementia remains uncertain.

Background Currently, no single biomarker can reliably identify preclinical Alzheimer’s disease (AD), particularly at or before the mild cognitive impairment (MCI) stage. Given the heterogeneity of MCI, integrative approaches are needed to improve early risk stratification.